<DOC>
	<DOCNO>NCT00671034</DOCNO>
	<brief_summary>This randomize clinical trial study give calaspargase pegol together combination chemotherapy see well work compare give pegaspargase together combination chemotherapy treat young patient newly diagnose high-risk acute lymphoblastic leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell .</brief_summary>
	<brief_title>Calaspargase Pegol Pegaspargase Combination Chemotherapy Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine pharmacokinetic comparability EZN-2285 ( calaspargase pegol ) compare Oncaspar ( pegaspargase ) give intravenously induction consolidation patient high-risk ALL receiving augment Berlin-Frankfurt-Munster ( BFM ) therapy . SECONDARY OBJECTIVES : I . To describe pharmacodynamics ( PD ) EZN-2285 compare Oncaspar give intravenously induction consolidation patient high-risk ALL receiving augment BFM therapy . II . To determine end induction therapy day 29 minimal residual disease ( MRD ) patient randomize EZN-2285 contain regimen compare Oncaspar® contain regimen . III . To determine complete remission ( CR ) rate patient receive EZN-2285 day 29 induction compare Oncaspar . IV . To assess event-free survival ( EFS ) associate administration EZN-2285 give augment post Induction intensification therapy patient high-risk ALL compare Oncaspar . V. To determine proportion patient asparaginase level least 0.1 IU/mL proportion least 0.4 IU/mL day 4 , 15 , 22 29 induction compare Oncaspar . VI . To determine plasma cerebrospinal fluid ( CSF ) concentration asparagine administration EZN-2285 compare Oncaspar . VII . To assess immunogenicity EZN-2285 include detection bind neutralize antibody compare Oncaspar . VIII . To assess tolerability toxicity associate administration EZN-2285 give augment post induction intensification therapy patient high risk ALL compare Oncaspar . IX . To explore relationship terminal pharmacokinetics ( PK ) EZN-2285 presence antibody . OUTLINE : This multicenter study . Patients stratify accord response induction therapy ( slow early responder [ SER ] v rapid early responder [ RER ] . Patients randomize 1 2 treatment arm 2:1 ratio ( arm I : arm II ) ( patient randomize arm I receive study drug calaspargase pegol* ; patient randomize arm II receive study drug pegaspargase ) . INDUCTION THERAPY** ( ALL PATIENTS ) : Patients receive cytarabine intrathecally ( IT ) day 1 ; vincristine intravenously ( IV ) daunorubicin hydrochloride IV 15 minute day 1 , 8 , 15 , 22 ; prednisone orally IV twice daily ( BID ) day 1-28 ; study drug IV 1 hour day 4 ; methotrexate IT day 8 , 15* , 22* , 29 . Patients assessed response day 8 and/or day 15 day 29 . Patients achieve M1 marrow day 8 15 negative MRD ( i.e. , &lt; 0.1 % ) day 29 consider RER . Patients achieve M2 M3 marrow day 15 OR MRD &gt; = 0.1 % &lt; 1 % day 29 consider SER . Patients M3 bone marrow remove study . RER SER proceed consolidation therapy . Patients M2 marrow M1 marrow &gt; = 1 % MRD receive extend induction therapy . Patients also receive dexamethasone PO IV BID day 1-14 ( patient &lt; 10 year ) prednisone BID day 1-28 ( patient &gt; = 10 year ) NOTE : *For patient CNS3 disease . EXTENDED INDUCTION THERAPY** : Patients receive vincristine IV day 1 8 ; prednisone orally ( PO ) IV BID day 1-14 ; daunorubicin hydrochloride IV 15 minute day 1 ; study drug IV 1 hour day 4 . Patients assessed response day 43 . Patients achieve M1 MRD &lt; 1 % treat SER ( proceed consolidation therapy ) . All patient remove study . CONSOLIDATION THERAPY** ( ALL PATIENTS ) : Beginning day 36 ( completion induction therapy ) completion extend induction therapy , patient ( RER SER ) receive cyclophosphamide IV 30 minute day 1 29 ; cytarabine IV SC day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO day 1-14 29-42 ; vincristine IV day 15 , 22 , 43 , 50 ; study drug IV 1 hour day 15 43 ; methotrexate IT day 1 , 8 , 15* , 22* . Patients proceed interim maintenance I therapy . NOTE : *Omit dose patient CNS3 disease . INTERIM MAINTENANCE I** ( ALL PATIENTS ) : Patients receive vincristine IV methotrexate** IV day 1 , 11 , 21 , 31 , 41 ; study drug IV 1 hour day 2 22 ; methotrexate IT day 1 31 . Patients proceed delay intensification I therapy . DELAYED INTENSIFICATION I** ( ALL PATIENTS ) : Patients receive vincristine IV day 1 , 8 , 15 , 43 , 50 ; dexamethasone PO IV BID day 1-21 patient age 1-9 , day 1-7 15-21 patient age &gt; = 10 ; doxorubicin hydrochloride IV 15 minute day 1 , 8 , 15 ; study drug IV 1 hour day 4 43 ; cyclophosphamide IV 30 minute day 29 ; cytarabine IV subcutaneously ( SC ) day 29-32 36-39 ; thioguanine PO day 29-42 ; methotrexate IT day 1 , 29 , 36 . Patients treat RER proceed maintenance therapy . Patients treat SER ( i.e. , patient CNS3 disease diagnosis , pre-treated steroid , RERs mixed lineage leukemia [ MLL ] gene rearrangement ) proceed interim maintenance II follow delay intensification II . INTERIM MAINTENANCE II** ( SER ONLY ) : Patients receive vincristine IV , methotrexate IV , study drug IV , methotrexate IT interim maintenance I . DELAYED INTENSIFICATION II** ( SER ONLY ) : Beginning day 29 , patient ( except patient CNS3 disease ) receive 8 daily fraction cranial radiotherapy . All patient receive vincristine IV , dexamethasone PO IV , doxorubicin hydrochloride IV , study drug IV , cyclophosphamide IV , cytarabine IV SC , thioguanine PO , methotrexate IT delayed intensification I . Patients initially diagnose CNS3 disease receive cranial radiotherapy day 1-5 8-12 . Patients proceed maintenance therapy . MAINTENANCE THERAPY** ( ALL PATIENTS ) : Patients receive vincristine IV day 1 , 29 , 57 ; oral dexamethasone day 1-5 , 29-33 , 57-61 ; mercaptopurine PO day 1-84 ; methotrexate IT day 29 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . Treatment repeat every 12 week 2 year ( female patient ) 3 year ( male patient ) start interim maintenance I . NOTE : ** As per amendment # 4A , patient receive high-dose methotrexate instead Capizzi methotrexate stage therapy . CNS3 patient SER patient receive cranial irradiation receive plan therapy modification . NOTE : As per amendment # 4A , maximum number intrathecal treatment limit RER/SER/CNS3 status gender . Blood cerebrospinal fluid sample collect periodically correlative study , include immunogenicity , pharmacokinetic , pharmacodynamic study . After completion study therapy , patient follow every 2 month 2 year , every 3 month 1 year , every 6-12 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Patients must eligible enrolled AALL08B1 successor classification study Patients must newly diagnose highrisk B lymphoblastic leukemia ( World Health Organization [ WHO ] 2008 classification ) ( also term Bprecursor acute lymphoblastic leukemia ) White blood cell ( WBC ) &gt; = 50,000/μL patient age 19 OR WBC count patient age 1030 patient treat prior steroid Patients shall prior cytotoxic chemotherapy exception steroid intrathecal cytarabine ; intrathecal chemotherapy cytarabine allow prior registration patient convenience ; usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture ; ( Note : CNS status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment ) systemic chemotherapy must begin within 72 hour intrathecal therapy Patients receive prior steroid therapy eligible study ; dose duration previous steroid therapy carefully documented Pregnancy test negative result must obtain postmenarchal female Lactating female must agree breastfeed child study Patients Down syndrome exclude study Patients testicular leukemia diagnosis exclude study Pregnant female patient exclude study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>